{"organizations": [], "uuid": "6d70a08a82fff42a6bb275284419ee865810443e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180405.html", "section_title": "Archive News &amp; Video for Thursday, 05 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biogen-samsung-bioepis-to-settle-w/brief-biogen-samsung-bioepis-to-settle-with-abbvie-over-humira-biosimilar-idUSFWN1RI0F2", "country": "US", "domain_rank": 408, "title": "BRIEF-Biogen, Samsung Bioepis To Settle With AbbVie Over Humira Biosimilar", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.505, "site_type": "news", "published": "2018-04-05T21:29:00.000+03:00", "replies_count": 0, "uuid": "6d70a08a82fff42a6bb275284419ee865810443e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biogen-samsung-bioepis-to-settle-w/brief-biogen-samsung-bioepis-to-settle-with-abbvie-over-humira-biosimilar-idUSFWN1RI0F2", "ord_in_thread": 0, "title": "BRIEF-Biogen, Samsung Bioepis To Settle With AbbVie Over Humira Biosimilar", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "samsung", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "biogen inc", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 5 (Reuters) - Biogen Inc:\n* BIOGEN AND SAMSUNG BIOEPIS AGREE TO SETTLEMENT WITH ABBVIE ALLOWING COMMERCIALIZATION OF IMRALDIâ„¢ (ADALIMUMAB BIOSIMILAR) IN EUROPE\n* BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018\n* PRECISE TERMS OF AGREEMENT WITH ABBVIE ARE CONFIDENTIAL * UNDER TERMS OF AGREEMENT, ABBVIE WILL GRANT PATENT LICENSES FOR USE AND SALE OF IMRALDI IN EUROPE\n* COUNTRY BASIS * UNDER TERMS OF AGREEMENT, BIOGEN AND SAMSUNG BIOEPIS WILL MAKE ROYALTY PAYMENTS TO ABBVIE\n* COMPANIES HAVE AGREED TO DISMISS ALL PENDING PATENT LITIGATION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-05T21:29:00.000+03:00", "crawled": "2018-04-06T21:59:16.012+03:00", "highlightTitle": ""}